165 related articles for article (PubMed ID: 2671011)
1. Evidence for a 6.5-day minimum exoerythrocytic cycle for Plasmodium falciparum in humans and confirmation that immunization with a synthetic peptide representative of a region of the circumsporozoite protein retards infection.
Murphy JR; Baqar S; Davis JR; Herrington DA; Clyde DF
J Clin Microbiol; 1989 Jul; 27(7):1434-7. PubMed ID: 2671011
[TBL] [Abstract][Full Text] [Related]
2. Proteosome-hydrophobic 'foot' malaria peptide vaccines for Plasmodium falciparum and P. vivax.
Lowell GH; Ballou WR; Smith LF; Zollinger WD; Hockmeyer WT
Trans R Soc Trop Med Hyg; 1989; 83 Suppl():101-2. PubMed ID: 2696152
[TBL] [Abstract][Full Text] [Related]
3. Induction of protective immunity to malaria.
Anders RF; Brown GV; Coppel RL; Kemp DJ
Lepr Rev; 1986 Dec; 57 Suppl 2():245-53. PubMed ID: 3553798
[No Abstract] [Full Text] [Related]
4. Towards a malaria vaccine: what is in sight?
del Giudice G
Allergol Immunopathol (Madr); 1991; 19(3):129-35. PubMed ID: 1799171
[No Abstract] [Full Text] [Related]
5. Synthetic peptides as antigens for the detection of humoral immunity to Plasmodium falciparum sporozoites.
Zavala F; Tam JP; Masuda A
J Immunol Methods; 1986 Oct; 93(1):55-61. PubMed ID: 3534091
[TBL] [Abstract][Full Text] [Related]
6. Immunity to malaria and naturally acquired antibodies to the circumsporozoite protein of Plasmodium falciparum.
Hoffman SL; Wistar R; Ballou WR; Hollingdale MR; Wirtz RA; Schneider I; Marwoto HA; Hockmeyer WT
N Engl J Med; 1986 Sep; 315(10):601-6. PubMed ID: 3526148
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites.
Herrington DA; Clyde DF; Losonsky G; Cortesia M; Murphy JR; Davis J; Baqar S; Felix AM; Heimer EP; Gillessen D
Nature; 1987 Jul 16-22; 328(6127):257-9. PubMed ID: 2439920
[TBL] [Abstract][Full Text] [Related]
8. Immunization trials with the ring-infected erythrocyte surface antigen of Plasmodium falciparum in owl monkeys (Aotus vociferans).
Collins WE; Pappaioanou M; Anders RF; Campbell GH; Brown GV; Kemp DJ; Broderson JR; Coppel RL; Skinner JC; Procell PM
Am J Trop Med Hyg; 1988 Mar; 38(2):268-82. PubMed ID: 3281493
[TBL] [Abstract][Full Text] [Related]
9. Antibodies to the repetitive epitope of Plasmodium falciparum circumsporozoite protein in a rural Tanzanian community: a longitudinal study of 132 children.
Del Giudice G; Engers HD; Tougne C; Biro SS; Weiss N; Verdini AS; Pessi A; Degremont AA; Freyvogel TA; Lambert PH
Am J Trop Med Hyg; 1987 Mar; 36(2):203-12. PubMed ID: 2435181
[TBL] [Abstract][Full Text] [Related]
10. Immunization of owl monkeys with the ring-infected erythrocyte surface antigen of Plasmodium falciparum.
Collins WE; Anders RF; Ruebush TK; Kemp DJ; Woodrow GC; Campbell GH; Brown GV; Irving DO; Goss N; Filipski VK
Am J Trop Med Hyg; 1991 Jan; 44(1):34-41. PubMed ID: 1996739
[TBL] [Abstract][Full Text] [Related]
11. The development of molecular vaccines against malaria sporozoites.
Ballou WR; Young JF; Cryz SJ; Sadoff JC
Adv Exp Med Biol; 1989; 251():295-313. PubMed ID: 2692428
[No Abstract] [Full Text] [Related]
12. Synthetic peptide vaccine confers protection against murine malaria.
Zavala F; Tam JP; Barr PJ; Romero PJ; Ley V; Nussenzweig RS; Nussenzweig V
J Exp Med; 1987 Nov; 166(5):1591-6. PubMed ID: 3316473
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of synthetic peptides from circumsporozoite protein of Plasmodium falciparum.
Ballou WR; Rothbard J; Wirtz RA; Gordon DM; Williams JS; Gore RW; Schneider I; Hollingdale MR; Beaudoin RL; Maloy WL
Science; 1985 May; 228(4702):996-9. PubMed ID: 2988126
[TBL] [Abstract][Full Text] [Related]
14. Plasmodium falciparum antigens as target molecules for a protective immunization against malaria: an up-to-date review.
Heidrich HG
Z Parasitenkd; 1986; 72(1):1-11. PubMed ID: 3515789
[No Abstract] [Full Text] [Related]
15. Malaria vaccine against sporozoites?
Nussenzweig V; Nussenzweig RS
Ann Inst Pasteur Immunol (1985); 1985; 136D(3):301-12. PubMed ID: 3913382
[TBL] [Abstract][Full Text] [Related]
16. Merozoite selection of erythrocytes by age and the induction of protective immunity.
Brown KN; Carlsson J; Jarra W
Blood Cells; 1990; 16(2-3):313-8. PubMed ID: 2096982
[No Abstract] [Full Text] [Related]
17. Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications.
Hoffman SL; Oster CN; Plowe CV; Woollett GR; Beier JC; Chulay JD; Wirtz RA; Hollingdale MR; Mugambi M
Science; 1987 Aug; 237(4815):639-42. PubMed ID: 3299709
[TBL] [Abstract][Full Text] [Related]
18. Experimental basis for the development of a synthetic vaccine against Plasmodium falciparum malaria sporozoites.
Nussenzweig V; Nussenzweig R
Ciba Found Symp; 1986; 119():150-63. PubMed ID: 2426050
[TBL] [Abstract][Full Text] [Related]
19. Characterization of antibodies to sporozoites in Plasmodium falciparum malaria and correlation with protection.
Webster HK; Brown AE; Chuenchitra C; Permpanich B; Pipithkul J
J Clin Microbiol; 1988 May; 26(5):923-7. PubMed ID: 2454941
[TBL] [Abstract][Full Text] [Related]
20. The circumsporozoite protein gene from NF54, a Plasmodium falciparum isolate used in malaria vaccine trials.
Caspers P; Gentz R; Matile H; Pink JR; Sinigaglia F
Mol Biochem Parasitol; 1989 Jun; 35(2):185-9. PubMed ID: 2671723
[No Abstract] [Full Text] [Related]
[Next] [New Search]
